In three previous webinars, panelists from Syneos Health discussed the definitions, goals and clinical-operational best practices — and organizational change — to enable a more diverse patient base to access clinical trials. One key remaining question for the future is, “what specific enforceable and quantifiable actions can be taken to drive and mandate meaningful and equitable change?” Despite many efforts over more than a decade, and recent impetus for change — as evidenced in the case studies from earlier in this webinar series — there is still much work to be done. In this final webinar of the series, the presenters explore how — or if — policy innovations, such as government-led mandates and incentives, can move the industry forward as one.
Speakers will examine the advantages and disadvantages of implementing penalties for failing to conduct inclusive trials, as well as rewards for leading the way on this issue. They will discuss examples from outside the biopharma industry that can serve to guide best practices, and identify opportunities for achieving true and lasting change. How can these carrots and sticks be used to overcome the social injustice that has become entrenched for generations? How can everyone work together with leadership in both the public and private sector, with organizations ranging from the Center for Medicare and Medicaid Services to the Bill and Melinda Gates Foundation, to create truly inclusive trials that deliver real results for all communities? Finally, what concrete steps can be taken to make clinical trials truly inclusive?
This four-part webinar series will identify obstacles that have to-date, and continue to, stifle appropriate patient diversity in clinical trials; unpack the organizational overhaul needed to effect change; share case studies where sponsors, patients, and investigators have come together to overcome hurdles; and explore how policy innovations that might include government-led mandates and incentives can move the industry forward as one.
Register for this webinar to learn how to optimize the patient diversity and inclusivity of clinical trials.
Stephen Keith, MD, MSPH, Medical Director, Syneos Health (Moderator)
Dr. Stephen Keith brings over 25 years of experience in the biopharma industry in vaccines development to his role as Medical Director at Syneos Health. He joined Syneos Health in 2018 as medical leader, and serves to support Patient Diversity initiatives.
Previously, Dr. Keith held C-level positions at three biotech companies, and was a General Partner at Glocap Advisors, a life sciences venture capital organization. Prior to entering the pharmaceutical industry, he served as Health Policy Advisor to the U.S. Senate Committee on Labor and Human Resources, under Senator Edward M. Kennedy.
An MD Pediatrician by training and practice, Dr. Keith currently serves on the Boards of Directors of National Medical Fellowships, and Community Health Charities.Message Presenter
Peter Pitts, President, Center for Medicine in the Public Interest
Peter Pitts is a Visiting Professor at the University of Paris Descartes Medical School, President of the Center for Medicine in the Public Interest and a Visiting Lecturer at the École Supérieure des Sciences Économiques et Commerciales (Paris and Singapore). He is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration. Peter is a member of the Council for International Organizations of Medical Sciences Expert Working Group to help advance patient involvement in the development and safe use of medicines. He is the lead author of many professional peer reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), an Advisory Board, member of the Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine. His new book is The Value Equation: A. Journey Through the Innovation Ecosystem in the Time of COVID. He is also the author of Common-Sense Healthcare for Common Sense Americans and Become Strategic or Die, widely recognized as a cutting- edge study of how leadership, in order to be successful over the long term, must be combined with strategic vision and ethical practice. He is the editor of Coincidence or Crisis, a discussion of global prescription medicine counterfeiting and Physician Disempowerment: A Transatlantic Malaise.Message Presenter
Who Should Attend?
This webinar is for biopharmaceutical leaders who are involved in:
- Clinical Trial Protocol Design
- Clinical Operations
- Patient Recruitment & Retention
- Patient Engagement
- Medical & Scientific Affairs
- Market Access
- Healthcare Diversity
What You Will Learn
In this webinar, attendees will:
- LEARN about what regulations from other fields could be useful models for creating more diverse clinical trials
- UNDERSTAND the benefits of inclusive trials, not just for the studies themselves but the communities as a whole
- DISCUSS how to reward organizations for creating truly equitable clinical trials
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.